1-3 of 3
Susan J. Faas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS

Clinical Trials & Observations
Roxanne Cofiell, Anjli Kukreja, Krystin Bedard, Yan Yan, Angela P. Mickle, Masayo Ogawa, Camille L. Bedrosian, Susan J. Faas
Journal: Blood
Blood (2015) 125 (21): 3253–3262.
https://doi.org/10.1182/blood-2014-09-600411
Published: 2015
Includes: Supplemental data
Journal Articles

First-In-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) In Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)

Daruka Mahadevan, MD, PhD, Mark C Lanasa, MD, PhD, Maria Whelden, RN, Susan J Faas, PhD, Terrie L Ulery, PhD, Anjli Kukreja, PhD, Lan Li, MS, MD, Camille L Bedrosian, MD, Leonard T Heffner, MD
Journal: Blood
Blood (2010) 116 (21): 2465.
https://doi.org/10.1182/blood.V116.21.2465.2465
Published: 2010
Journal Articles

Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti–DC-SIGN antibody

Paul J. Tacken, I. Jolanda M. de Vries, Karlijn Gijzen, Ben Joosten, Dayang Wu, Russell P. Rother, Susan J. Faas, Cornelis J. A. Punt, Ruurd Torensma, Gosse J. Adema, Carl G. Figdor
Journal: Blood
Blood (2005) 106 (4): 1278–1285.
https://doi.org/10.1182/blood-2005-01-0318
Published: 2005
Includes: Multimedia, Supplemental data